Jounce Therapeutics Investor Relations Material
Latest events
Business Combination
Jounce Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Jounce Therapeutics Inc
Access all reports
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company focused on developing novel treatments for cancer. Its lead product candidate is RT001, an episomal antibody-encoding nanovaccine that utilizes codeveloped CLIP-Seq technology to target patient-specific tumor neoantigens and reduce the incidence of off-target toxicity resulting from personalized vaccines. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States